Regeneron

YTD

ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.

CEO

Leonard S. Schleifer

CEOLeonard S. Schleifer

Employees

15,410

Employees15,410

Headquarters

Tarrytown, New York

HeadquartersTarrytown, New York

Founded

1988

Founded1988

Employees

15,410

Employees15,410

REGN Key Statistics

Market cap

87.33B

Market cap87.33B

Price-Earnings ratio

18.76

Price-Earnings ratio18.76

Dividend yield

0.48%

Dividend yield0.48%

Average volume

960.90K

Average volume960.90K

High today

$813.63

High today$813.63

Low today

$788.62

Low today$788.62

Open price

$808.80

Open price$808.80

Volume

611.50K

Volume611.50K

52 Week high

$821.11

52 Week high$821.11

52 Week low

$541.00

52 Week low$541.00

Stock Snapshot

With a market cap of 87.33B, Regeneron(REGN) trades at $805.30. The stock has a price-to-earnings ratio of 18.76 and currently yields dividends of 0.48%.

As of 2026-08-11, Regeneron(REGN) stock has fluctuated between $788.62 and $813.63. The current price stands at $805.30, placing the stock +2.1% above today's low and -1.0% off the high.

Regeneron(REGN) shares are trading with a volume of 611.5K, against a daily average of 960.9K.

During the past year, Regeneron(REGN) stock moved between $541.00 at its lowest and $821.11 at its peak.

REGN News

Simply Wall St 9h

Regeneron Pharmaceuticals Following Earnings And Buybacks, Is The Valuation Case Still Intact?

Advertisement Regeneron Pharmaceuticals earnings, dividend and buybacks come into focus Regeneron Pharmaceuticals (REGN) has drawn investor attention after re...

TipRanks 5d

Regeneron announces Health Canada approval of new indication for Libtayo

Regeneron (REGN) Canada announced that Health Canada has issued a Notice of Compliance for Libtayo for the adjuvant treatment of adult patients with cutaneous s...

TipRanks 6d

Regeneron Targets Next‑Gen Cancer Immunotherapy With New Phase 1/2 Trial

Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, mo...

Analyst ratings

63%

of 30 ratings

Buy

63.3%

Hold

36.7%

Sell

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.